Avalo CFO sells 10K shares after option exercise
Avalo Therapeutics’ CFO exercised options and sold 10,185 shares under a pre-arranged Rule 10b5-1 trading plan, while retaining a substantial remaining option position.
Rhea-AI Filing Summary
Avalo Therapeutics, Inc. (AVTX) reported that Chief Financial Officer Christopher Ryan Sullivan exercised stock options for 10,185 shares of common stock at an exercise price of $8.04 per share on September 10, 2026, then sold 10,185 shares of common stock at a weighted average price of $17.6197 per share in multiple transactions. These trades were effected pursuant to a Rule 10b5-1 trading plan adopted on May 18, 2026. Following the option exercise, he continued to hold 105,815 options to purchase common stock at $8.04 per share, expiring on January 28, 2035, with the option vesting 25% on January 28, 2026 and the balance in equal monthly installments over the following three years, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,185 shares ($98K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Sullivan Christopher Ryan
Role
Chief Financial Officer
Sold
10,185 shs ($179K)
Approx. gross sale proceeds
$179K
Approx. exercise cost
$82K
Approx. pre-tax spread
$98K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F3 | 10,185 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 10,185 | $8.04 | $82K |
| Sale | Common Stock F1, F2 | 10,185 | $17.6197 | $179K |
Holdings After Transaction:
Stock Option (Right to Buy) — 105,815 contracts (Direct);
Common Stock — 39,900 shares (Direct)
Footnotes (3)
- F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026.
- F2. The reported securities were sold in multiple transactions at prices ranging from $17.17 to $17.95. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.
- F3. The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on such vesting date.
Key Figures
Shares exercised: 10,185 shares
Exercise price: $8.04 per share
Shares sold: 10,185 shares
+5 more
8 metrics
Shares exercised
10,185 shares
Stock options exercised for common stock on September 10, 2026
Exercise price
$8.04 per share
Exercise price of the stock options converted into common stock
Shares sold
10,185 shares
Common shares sold on September 10, 2026 after option exercise
Weighted average sale price
$17.6197 per share
Weighted average price for shares sold in multiple transactions
Sale price range
$17.17–$17.95 per share
Range of prices for the multiple sale transactions
Options remaining
105,815 options
Stock options to buy common stock held after the reported transactions
Option expiration date
January 28, 2035
Expiration date of the reported stock option position
Rule 10b5-1 plan adoption date
May 18, 2026
Date the reporting person adopted the trading plan used for these transactions
Key Terms
Rule 10b5-1 trading plan, vests twenty-five percent (25%), equal monthly installments, continued service
4 terms
Rule 10b5-1 trading plan regulatory
"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 18, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
vests twenty-five percent (25%) financial
"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments..."
equal monthly installments financial
"The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years..."
continued service other
"...over the following three (3) years, subject to the Reporting Person's continued service on such vesting date."
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What transactions did Avalo Therapeutics (AVTX) CFO report on September 10, 2026?
He exercised options for 10,185 shares of Avalo Therapeutics common stock at $8.04 per share and then sold 10,185 shares in multiple transactions at a weighted average price of $17.6197 per share on the same date.
Were the AVTX insider transactions made under a Rule 10b5-1 plan?
Yes. The filing states that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 18, 2026, indicating they were executed according to a pre-arranged trading schedule.
How many Avalo Therapeutics (AVTX) options does the CFO hold after these transactions?
After the September 10, 2026 option exercise, the reporting person held 105,815 stock options to purchase Avalo Therapeutics common stock at an exercise price of $8.04 per share, with these options scheduled to expire on January 28, 2035.
What is the vesting schedule of the Avalo Therapeutics stock option involved?
The filing explains that the stock option vests 25% on January 28, 2026, and the remainder vests in equal monthly installments over the following three years, subject to the reporting person’s continued service on each vesting date.
AI-generated analysis. How Rhea-AI works. Not financial advice.
